ArticleJournal of cheminformatics2022
European Registry of Materials: global, unique identifiers for (undisclosed) nanomaterials.
Article in Journal of cheminformatics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Wisdom of Crowds for Supporting the Safety Evaluation of Nanomaterials.Environmental science & technology · 2025Article
- High-throughput screening data generation, scoring and FAIRification: a case study on nanomaterials.Journal of cheminformatics · 2025Article
- Instance maps as an organising concept for complex experimental workflows as demonstrated for (nano)material safety research.Beilstein journal of nanotechnology · 2025Article
- CompSafeNano project: NanoInformatics approaches for safe-by-design nanomaterials.Computational and structural biotechnology journal · 2025Article
- In silico assessment of nanoparticle toxicity powered by the Enalos Cloud Platform: Integrating automated machine learning and synthetic data for enhanced nanosafety evaluation.Computational and structural biotechnology journal · 2024Article
- A template wizard for the cocreation of machine-readable data-reporting to harmonize the evaluation of (nano)materials.Nature protocols · 2024Review
- From papers to RDF-based integration of physicochemical data and adverse outcome pathways for nanomaterials.Journal of cheminformatics · 2024Article
- Data-Driven Quantitative Intrinsic Hazard Criteria for Nanoproduct Development in a Safe-by-Design Paradigm: A Case Study of Silver Nanoforms.ACS applied nano materials · 2023Article
- The alamar blue assay in the context of safety testing of nanomaterials.Frontiers in toxicology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Management of nanomaterials and nanosafety data needs to operate under the FAIR (findability, accessibility, interoperability, and reusability) principles and this requires a unique, global identifier for each nanomaterial. Existing identifiers may not always be applicable or sufficient to definitively identify the specific nanomaterial used in a particular study, resulting in the use of textual descriptions in research project communications and reporting. To ensure that internal project documentation can later be linked to publicly released data and knowledge for the specific nanomaterials, or even to specific batches and variants of nanomaterials utilised in that project, a new identifier is proposed: the European Registry of Materials Identifier. We here describe the background to this new identifier, including FAIR interoperability as defined by FAIRSharing, identifiers.org, Bioregistry, and the CHEMINF ontology, and show how it complements other identifiers such as CAS numbers and the ongoing efforts to extend the InChI identifier to cover nanomaterials. We provide examples of its use in various H2020-funded nanosafety projects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.